Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Review clarifies depression, anxiety risk among hidradenitis suppurativa patients

Key clinical point: Depression and anxiety are common comorbidities in patients with hidradenitis suppurativa (HS).

Major finding: The prevalence of depression and anxiety, respectively, in HS patients was 16.9% and 4.9%.

Study details: The data come from a systematic review and meta-analysis of studies that included 40,307 adults with HS.

Disclosures: Dr. Machado had no financial conflicts to disclose. Several coauthors disclosed relationships with Galderma, LEO Pharma, Janssen, Novartis, AbbVie, Celgene, Naos, Lilly, Sanofi, Valeant, and La Roche–Posay.


Machado M et al. JAMA Dermatol. 2019 June 5. doi: 10.1001/jamadermatol.2019.0759.